NRX Pharmaceuticals, Inc. · GETTEX:B1Q

NRX Pharmaceuticals, Inc. financial statements

NRX Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2018FY2017
Revenue1.23M00000
Cost of revenue505.0K05.00K4.00K2.00K2.00K1.01M
Gross profit720.0K-5.00K-5.00K-4.00K-2.00K-2.00K-1.01M
Research and development3.78M6.20M13.4M17.0M20.3M10.6M3.50K
Selling, general and administrative13.1M13.5M14.2M27.4M74.9M11.4M2.77K1.01M134.5K
Operating income-16.2M-18.5M-27.8M-44.3M-115.8M-51.4M-713.2K-1.01M-1.19K-134.5K
Depreciation and amortization70.0K5.00K5.00K4.00K2.00K2.00K11.09M52.5K
EBITDA-16.2M-18.5M-27.8M-44.3M-115.8M-51.4M-713.2K82.4K-82.0K
Interest expense671.0K230.0K120.0K4.58M18.0K56.0K000
Income before tax-28.6M-25.1M-30.1M-39.8M-93.1M-51.8M492.6K82.4K-1.19K-105.0K
Income tax000-4.58M-21.3M17.8K84.2K16.3K0
Net income-28.6M-25.1M-30.1M-39.8M-93.1M-51.8M408.4K66.1K-1.19K-105.0K
Earnings per share, basic-1.34-2.36-3.98-0.60-1.98-1.51-0.11-0.290.00-0.12
Earnings per share, diluted-0.60-1.98-1.51-0.11-0.290.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2018FY2017
Cash and equivalents7.80M1.44M4.59M20.1M27.6M1.86M877.4K11.1K77.1K449.4K
Short-term investments5.97M32.0M70.8M69.0M
Receivables161.0K06.00K7.00K0831.4K
Inventory-6.00K-7.00K214.0K
Current assets8.89M3.30M6.88M25.8M32.7M2.93M69.5K30.2K123.8K536.4K
Property, plant and equipment63.0K10.0K
Goodwill1.79M0
Total assets13.0M3.65M7.32M25.8M32.7M2.94M32.1M70.8M69.9M69.6M
Accounts payable4.27M4.13M4.63M2.08M3.69M3.15M622.4K551.1K85.7K
Current liabilities28.6M21.9M19.0M15.6M11.9M46.2M622.4K567.4K375.6K93.2K
Long-term debt5.01M2.82M2.67M1.95M690.0K
Total debt631.0K6.58M9.16M10.5M518.0K797.0K1.95M690.0K
Total liabilities28.9M26.9M19.0M18.4M11.9M46.7M2.57M1.26M93.2K
Shareholders' equity-15.9M-23.2M-11.7M7.41M20.8M-43.8M-4.84M5.00M5.00M69.5M
Shares outstanding31.7M14.6M8.39M66.4M58.8M43.0M2.84M2.73M2.64M903.5K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2018FY2017
Cash from operations-14.1M-10.6M-21.7M-39.8M-37.7M-2.27M-792.7K-473.2K-30-135.8K
Capital spending00-3.00K-10.0K-7.00K-2.00K-100
Free cash flow-14.1M-10.6M-21.7M-39.8M-37.7M-2.27M-792.7K-473.2K-135.8K
Cash from investing-2.81M0-3.00K-10.0K-7.00K-2.00K40.2M-647.4K0-69.0M
Cash from financing23.3M7.49M6.20M32.2M63.5M3.25M-39.5M682.5K82.5K69.6M
Share buybacks-26.3M-40.7M70.0M
Change in cash6.35M-3.15M-15.5M-7.55M25.7M982.0K-11.1K-438.3K82.5K449.4K